Literature DB >> 28625507

Contemporary Patterns of Care and Outcomes of Men Found to Have Lymph Node Metastases at the Time of Radical Prostatectomy.

Piotr Zareba1, James Eastham2, Peter T Scardino2, Karim Touijer2.   

Abstract

PURPOSE: A thorough understanding of the natural history and consensus regarding the optimal management of pathological lymph node positive (pN1) prostate cancer are lacking. Our objective was to describe patterns of care and outcomes of a contemporary cohort of men with pN1 prostate cancer.
MATERIALS AND METHODS: We used the National Cancer Database to identify 7,791 men who were found to have lymph node metastases at radical prostatectomy. Multinomial logistic regression and Cox proportional hazards regression were used to identify patient, tumor and facility characteristics associated with the choice of management strategy after radical prostatectomy and overall survival, respectively.
RESULTS: Initial post-prostatectomy management was observation in 63% of the men, androgen deprivation therapy alone in 20%, radiation therapy alone in 5%, and androgen deprivation therapy and radiation therapy in 13%. Younger age, lower comorbidity burden, higher grade and stage, and positive surgical margins were associated with a higher likelihood of receiving combination therapy. Grade group 4-5 disease, pT3b-T4 disease, positive surgical margins and a higher number of positive lymph nodes were independent predictors of worse overall survival. The adjusted 10-year overall survival probability decreased from 84% to 32% with the presence of an increasing number of adverse prognostic factors. Treatment with combined androgen deprivation therapy and radiation therapy was associated with better overall survival (multivariable HR 0.69, 95% CI 0.52-0.92, p = 0.010 for combination therapy vs observation).
CONCLUSIONS: Patient and tumor characteristics are associated with the choice of management strategy after radical prostatectomy and survival in men with pN1 prostate cancer. Multimodal therapy may be of benefit in this patient population.
Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  lymph node excision; lymphatic metastasis; mortality; prostatectomy; prostatic neoplasms

Mesh:

Year:  2017        PMID: 28625507      PMCID: PMC6049661          DOI: 10.1016/j.juro.2017.06.062

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

Authors:  Edward M Messing; Judith Manola; Jorge Yao; Maureen Kiernan; David Crawford; George Wilding; P Anthony di'SantAgnese; Donald Trump
Journal:  Lancet Oncol       Date:  2006-06       Impact factor: 41.316

2.  Treatment of lymph node-positive prostate cancer: teaching old dogmas new tricks.

Authors:  Alberto Briganti; Niccolò M Passoni; Firas Abdollah; Alessandro Nini; Francesco Montorsi; R Jeffrey Karnes
Journal:  Eur Urol       Date:  2013-07-10       Impact factor: 20.096

3.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

Authors:  Scott E Eggener; Peter T Scardino; Patrick C Walsh; Misop Han; Alan W Partin; Bruce J Trock; Zhaoyong Feng; David P Wood; James A Eastham; Ofer Yossepowitch; Danny M Rabah; Michael W Kattan; Changhong Yu; Eric A Klein; Andrew J Stephenson
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

4.  Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer.

Authors:  Firas Abdollah; Maxine Sun; Rodolphe Thuret; Lars Budäus; Claudio Jeldres; Markus Graefen; Alberto Briganti; Paul Perrotte; Patrizio Rigatti; Francesco Montorsi; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2010-09-28       Impact factor: 20.096

5.  The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Authors:  Lorenzo Bianchi; Alessandro Nini; Marco Bianchi; Giorgio Gandaglia; Nicola Fossati; Nazareno Suardi; Marco Moschini; Paolo Dell'Oglio; Riccardo Schiavina; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2015-12-31       Impact factor: 20.096

6.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Authors:  Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

7.  Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy.

Authors:  Joshua R Kaplan; Keith J Kowalczyk; Tudor Borza; Xiangmei Gu; Stuart R Lipsitz; Paul L Nguyen; David F Friedlander; Quoc-Dien Trinh; Jim C Hu
Journal:  BJU Int       Date:  2013-04-02       Impact factor: 5.588

8.  Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center.

Authors:  F Abdollah; N Suardi; A Gallina; M Bianchi; M Tutolo; N Passoni; N Fossati; M Sun; P dell'Oglio; A Salonia; P I Karakiewicz; P Rigatti; F Montorsi; A Briganti
Journal:  Ann Oncol       Date:  2013-03-18       Impact factor: 32.976

9.  Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.

Authors:  Firas Abdollah; R Jeffrey Karnes; Nazareno Suardi; Cesare Cozzarini; Giorgio Gandaglia; Nicola Fossati; Damiano Vizziello; Maxine Sun; Pierre I Karakiewicz; Mani Menon; Francesco Montorsi; Alberto Briganti
Journal:  J Clin Oncol       Date:  2014-09-22       Impact factor: 44.544

10.  Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer.

Authors:  Marianne Schmid; Christian P Meyer; Gally Reznor; Toni K Choueiri; Julian Hanske; Jesse D Sammon; Firas Abdollah; Felix K H Chun; Adam S Kibel; Reginald D Tucker-Seeley; Philip W Kantoff; Stuart R Lipsitz; Mani Menon; Paul L Nguyen; Quoc-Dien Trinh
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

View more
  4 in total

1.  [Trivialization of prostate cancer? : Stage shift and possible causes].

Authors:  M Saar; M S K M Abdeen; C Niklas; Z T F Al-Kailani; S Siemer; M Stöckle
Journal:  Urologe A       Date:  2019-12       Impact factor: 0.639

Review 2.  Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy.

Authors:  Masaki Shiota; Leandro Blas; Masatoshi Eto
Journal:  Cancers (Basel)       Date:  2022-05-30       Impact factor: 6.575

Review 3.  Patients with Positive Lymph Nodes after Radical Prostatectomy and Pelvic Lymphadenectomy-Do We Know the Proper Way of Management?

Authors:  Bartosz Małkiewicz; Miłosz Knura; Małgorzata Łątkowska; Maximilian Kobylański; Krystian Nagi; Dawid Janczak; Joanna Chorbińska; Wojciech Krajewski; Jakub Karwacki; Tomasz Szydełko
Journal:  Cancers (Basel)       Date:  2022-05-08       Impact factor: 6.575

4.  Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer.

Authors:  Masaki Shiota; Dai Takamatsu; Takahiro Kimura; Kojiro Tashiro; Yoshiyuki Matsui; Ryotaro Tomida; Ryoichi Saito; Masakazu Tsutsumi; Akira Yokomizo; Yoshiyuki Yamamoto; Kohei Edamura; Makito Miyake; Shuichi Morizane; Takayuki Yoshino; Akihiro Matsukawa; Shintaro Narita; Ryuji Matsumoto; Takashi Kasahara; Kohei Hashimoto; Hiroaki Matsumoto; Masashi Kato; Shusuke Akamatsu; Akira Joraku; Manabu Kato; Takahiro Yamaguchi; Toshihiro Saito; Tomoyuki Kaneko; Atsushi Takahashi; Takuma Kato; Shinichi Sakamoto; Hideki Enokida; Hidenori Kanno; Naoki Terada; Shigetaka Suekane; Naotaka Nishiyama; Masatoshi Eto; Hiroshi Kitamura
Journal:  Cancer Sci       Date:  2022-05-17       Impact factor: 6.518

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.